Global Clinical Trials for Alzheimer s Disease

Produk Detail:
  • Author : Menghis Bairu
  • Publisher : Academic Press
  • Pages : 432 pages
  • ISBN : 0124115306
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Global Clinical Trials for Alzheimer s Disease

Download or Read online Global Clinical Trials for Alzheimer s Disease full in PDF, ePub and kindle. this book written by Menghis Bairu and published by Academic Press which was released on 28 August 2013 with total page 432 pages. We cannot guarantee that Global Clinical Trials for Alzheimer s Disease book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer’s disease. Written by leading experts with hands-on experience in designing and running global Alzheimer’s disease and other neurodegenerative diseases clinical trials A step-by-step guide that provides critical information on the design, conduct and standardization necessary to effectively execute clinical trials and accelerate drug development in this area Includes practical examples, ethical considerations, lessons learned and other valuable tools to aid the planning and implementation of Alzheimer’s disease global clinical trials in emerging markets and developing countries

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer s Disease
  • Author : Menghis Bairu,Michael Weiner
  • Publisher : Academic Press
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Hans J. Möbius
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Regulatory approval of the first rational AD therapeutic tacrine occurred in 1993, followed by the approval of three other, AChEIs, and the NMDA antagonist memantine in 2002 (EMA) and 2003 (FDA) respectively. Since then, despite an enormous research and development effort, the past 10 years have seen a series of failures to translate pathophysiological understanding of dementia into new medicines. This includes a move away from neurotransmission to a focus on underlying pathological processes. The major reason for these failures was probably the continued

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Michel Grothe,Jens Kurth,Harald Hampel,Bernd J. Krause,Stefan Teipel
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

In-vivo imaging markers of neuronal changes related to Alzheimer’s disease (AD) are ideally suited to be employed as diagnostic markers for early and differential diagnosis of AD as well as for the assessment of neurobiological effects of medical treatments in clinical trials. Novel molecular imaging techniques enable in-vivo detection of cerebral amyloid pathology, whereas magnetic resonance imaging (MRI)-based techniques, such as volumetric MRI and diffusion tensor imaging (DTI), provide structural lesion markers that allow tracking disease progression from

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Peter Schüler,Klaudius Siegfried,Michael Hüll
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

To date (2013), we have witnessed over 100 years of research on Alzheimer’s disease (AD). In the past century, this gave new and deep insights into its pathophysiology. However, no new treatment with an innovative mode of action has found its way to the patients since the first targeted therapies with cholinergic drugs like Tacrin. So far A-beta and related targets have shown negative results in pivotal Phase III studies, after showing promising trends in Phase II. Thus the question arises

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Jeffrey Cummings,Kate Zhong
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Globalization is increasingly common as a means of more rapidly recruiting patients, shortening clinical trials, abbreviating clinical development cycle times, and preparing for marketing in non-US markets. Globalization refers to the inclusion of trial sites in three or more international regions. Globalization is common and most drug development programs include both US and non-US sites. There has been limited evaluation of the transnational performance of clinical trial instrumentation used in drug development programs. The performance across nations, languages and cultures

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Tal Burt,Lynne Hughes,Amir Kalali,P. Murali Doraiswamy
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

There is considerable interest, both nationally and internationally, in conducting dementia research in India. Motivated by a rapid increase in the aging population and a desire for indigenous, self-sufficient healthcare and medical research, dementia research in India is on course for rapid growth in the coming years. Several challenges will have to be overcome along the way. A solid and general clinical research culture and a supportive healthcare system, both tailored to the specific needs of the dementia field and

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : H. Michael Arrighi
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Alzheimer’s disease (AD) confers an additional risk of death. The magnitude of this impact is related to the person’s underlying mortality and current AD stage. When planning clinical trials, estimating the number of deaths prior to study initiation, and periodically during the study as participants are enrolled, assists in providing an informative context, particularly if there are few life events. Additionally, deaths have the potential to introduce a bias, thus, equal follow-up needs to ensure for participants assigned

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Tiia Ngandu,Francesca Mangialasche,Miia Kivipelto
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Today there are more than 36 million demented persons worldwide. With the aging of populations, the prevalence of dementia and Alzheimer’s disease (AD) is expected to more than triple in the coming 40 years. Besides high age and genetic factors, evidence from observational studies shows that many modifiable vascular and lifestyle-related risk factors at midlife affect the risk of the disease. Control of vascular and metabolic risk factors, healthy diet, and maintenance of AN active lifestyle (physical, mental, and social components)

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Roy W. Jones
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Current drug treatments for Alzheimer’s disease (AD) appear to be symptomatic. There is an increasing priority to find effective and safe disease-modifying and preventive treatment strategies for cognitive decline, AD, and dementia. Recent developments have allowed the identification of possible pathogenic processes and pathways, and potential targets for intervention. Cerebrospinal fluid (CSF) biomarkers of ß-amyloid and tau, and neuroimaging including amyloid PET tracer retention show that the pathogenic process begins many years before symptoms appear. A number of preventive

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer   s Disease
  • Author : Lynne Hughes,Spencer Guthrie
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

This chapter reviews significant recent clinical trials involving potential disease-modifying drugs, including active immunotherapy, passive immunotherapy, γ-secretase inhibitors and modulators, β-secretase inhibitors, and amyloid-beta (Aβ) anti-aggregants. The challenges and opportunities involved in global trials are then discussed, such as variability in diagnosis and patient selection; patient endpoints for both symptomatic therapies and disease-modifying drugs; rater training and global validation of rating scales; competition to recruit the pool of patients available for clinical trials; and emerging logistical concerns related to the

Proceedings of 9th International Conference on Alzheimer s Disease Dementia 2017

Proceedings of 9th International Conference on Alzheimer   s Disease   Dementia 2017
  • Author : ConferenceSeries
  • Publisher : ConferenceSeries
  • Release : 20 January 2022
GET THIS BOOK Proceedings of 9th International Conference on Alzheimer s Disease Dementia 2017

October 16-18, 2017 Rome, Italy Key Topics : Managing Dementia, Diagnosis and Symptoms, Imaging Techniques, Pathophysiology and Disease Mechanisms, Geriatrics and Cognitive Disorder, Amyloid Protein in Dementia, Care Practice and Awareness, Therapeutic Targets, Animal Models and Translational Medicine, Vascular Dementia, Alzheimers disease and Dementia, Traumatic brain injury, Dementia with Lewy Bodies, Alzheimers clinical trials and studies,

Encyclopedia of Alzheimer s Disease

Encyclopedia of Alzheimer s Disease
  • Author : Elaine A. Moore,Lisa Moore
  • Publisher : Unknown
  • Release : 20 January 2022
GET THIS BOOK Encyclopedia of Alzheimer s Disease

The second edition contains updated resources, research institution information and a listing of treatment and care facilities in the United States. Additions to the encyclopedia section include advances in Alzheimers disease research, genetics, diagnostic procedures, treatment, alternative medicine, brain plasticity, risk factors, clinical trial information, nursing home safety, and preventive measures. In addition the book describes medical treatments used in other countries and the results of collaborative efforts such as the recent global imaging test initiatives and the Prevent Alzheimers

ABC s of Alzheimers Disease

ABC s of Alzheimers Disease
  • Author : Bruce Bauer
  • Publisher : Covenant Books, Inc.
  • Release : 23 May 2019
GET THIS BOOK ABC s of Alzheimers Disease

ABCs of Alzheimer's Disease: a Shared Reality by Me and My Shadow is a story of Bruce and Ethel's Alzheimer's disease (AD) journey, along with a history of AD from autopsies to PET scan research, including technology and genetic discoveries. The book is a realistic, short, comprehensive, evidence-based, description of Alzheimer's disease (AD). It describes AD research, including clinical trials, a simplified understanding of the brain, and the experiences of patient/caregiver persistence and journey as well as hope for

Alzheimer s Disease

Alzheimer s Disease
  • Author : Harald Hampel,Maria C. Carrillo
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 20 January 2022
GET THIS BOOK Alzheimer s Disease

How current biomarkers are modernizing the diagnosis of Alzheimer's disease Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer's disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel

Aluminium and Alzheimer s Disease

Aluminium and Alzheimer s Disease
  • Author : C. Exley
  • Publisher : Elsevier
  • Release : 03 July 2001
GET THIS BOOK Aluminium and Alzheimer s Disease

The subject of aluminium and Alzheimer's disease has been plagued with controversy. This controversy has served to obscure much of the scientific research in this field, and subsequently has obscured the possibility that aluminium is a contributory factor in the aetiology of Alzheimer's disease. This book brings together many of the world's leading scientists researching aluminium and life and contains their critical summaries on the known facts about aluminium toxicity in man and to offer an opinion on the implications